20Dec 2018

IMPACT OF TYPE 2 DIABETES IN NON ST-ELEVATION MYOCARDIAL INFARCTION (NSTEMI).

  • Cardiology Department, Military hospital, Rabat, Morocco.
Crossref Cited-by Linking logo

Plum Print visual indicator of research metrics
  • Captures
    • Readers: 1
see details

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Objetives: The aim of this work is to expose the experience of our center in managing severe multi vessel coronary artery disease in diabetic NSTEMI patients. Methods:This is a retrospective study of 105 patients admitted for a high risk non ST-Elevation Myocardial Infarction (NSTEMI) to the cardiology department of the military hospital, Rabat, Morocco. Data was collected from january 2013 to december 2014. We enrolled patients in two groups: Group 1: diabetic patients (N 53) and Group 2: non diabetic patients (N 52). Results: The mean age was almost comparable between the 2 groups: 62 years in diabetics against 60 years in non-diabetics. The mean diabetes duration was about 8.6 years.Diabetic patients are more likely to develop arterial hypertension; smoking is the most important cardiovascular risk factor in non-diabetic group. Tri-truncular coronary lesion was more frequent in diabetics (55%), whereas non-diabetic patients had more mono-truncular lesions (53%). 59% of diabetic patients underwent PCI vs 53 % in non diabetic group, 26% of diabetic patients underwent CABG. 15% of diabetic group and 16% of non diabetic group were managed by medical treatment only. For in-hospital MACE, there were no signicant differences in outcomes between the 2 groups. (Group1 : 10,4% vs Group 2 : 10,5%, p :0,6). Conclusions: In diabetic NSTEMI patients, coronary artery disease was more severe; in our center, PCI was non inferior in term of intra hospital MACE compared to CABG.

  1. GrupaRoboczaEuropejskiegoTowarzystwaKardiologicznego (ESC) do sprawcukrzycy, stanuprzedcukrzycowego i chor?bukładusercowo-naczyniowegowewsp?łpracy z EuropejskimTowarzystwemBadańnadCukrzycą (EASD). Wytyczne ESC dotyczącecukrzycy, stanuprzedcukrzycowego i chor?bukładusercowo-naczyniowegoopracowanewewsp?łpracy z EASD. Kardiol Pol 2013; 71 (supl. XI): 319-394.
  2. Etat de sant? de la population marocaine 2012, minist?re de la sant?.
  3. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. EuropeanDiabetesEpidemiology Group. Diabetesepidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999; 354: 617-621.
  4. The DECODE Study Group. Is the currentdefinition for diabetes relevant to mortalityriskfrom all causes and cardiovascular and noncardiovasculardiseases? Diabetes Care 2003; 26: 688-696.
  5. Ning F, Tuomilehto J, Py?r?l? K, Onat A, S?derberg S, Qiao Q. DECODE Study Group. Cardiovasculardiseasemortality in Europeans in relation to fasting and 2-h plasma glucose levelswithin a normoglycemic range. Diabetes Care 2010; 33: 2211-2216.
  6. Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, Marre M, Steg PG, Gowda N, Gore JM. GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. ArchIntern Med 2004; 164: 1457-1463.
  7. Keymel S, Heinen Y, Balzer J, Rassaf T, Kelm M, Lauer T, Heiss C. Characterization of macro- and microvascularfunction and structure in patients with type 2 diabetesmellitus. Am J Cardiovasc Dis 2011; 1: 68-75.
  8. Ledru F, Ducimeti?re P, Battagia S, et al. New diagnostic criteria for diabetes and coronaryarterydisease: insights from an angiographicstudy. J Am CollCardiol 2001;37:1543?50.
  9. BypassAngioplastyRevascularization Investigation 2 DiabetesStudy Group. Baseline characteristics of patients withdiabetes and coronaryarterydiseaseenrolled in the BypassAngioplastyRevascularization Investigation 2 Diabetes (BARI 2D) trial. Am Heart J 2008; 156: 528-536.
  10. BARI 2D Study Group; Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronaryarterydisease. N Engl J Med 2009; 360: 2503-2515.
  11. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carri? D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, K?hler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ. Coronaryarterybypasssurgerycomparedwithpercutaneouscoronary interventions for multivesseldisease: a collaborative analysis of individual patient data fromtenrandomised trials. Lancet 2009; 373: 1190-1197.
  12. Bundhun PK, Wu ZJ, Chen MH. Coronaryarterybypasssurgerycomparedwithpercutaneouscoronary interventions in patients withinsulin-treated type 2 diabetesmellitus: asystematicreview and meta-analysis of 6 randomizedcontrolled trials. CardiovascDiabetol 2016; 15: 2.
  13. Franz-Josef Neumann(ESC Chairperson) (Germany), Miguel Sousa-Uva(EACTS Chairperson) (Portugal), Anders Ahlsson(Sweden), Fernando Alfonso (Spain), Adrian P. Banning (UK), Umberto Benedetto(UK), Robert A. Byrne (Germany), Jean-Philippe Collet (France), Volkmar Falk(Germany), Stuart J. Head(The Netherlands), Peter Ju ̈ ni (Canada), Adnan Kastrati (Germany), AkosKoller (Hungary), Steen D. Kristensen (Denmark), Josef Niebauer (Austria), Dimitrios J. Richter (Greece), Petar M. Seferovic (Serbia), Dirk Sibbing (Germany), Giulio G. Stefanini (Italy), Stephan Windecker (Switzerland), Rashmi Yadav(UK), Michael O. Zembala(Poland) 2018 ESC/EACTS Guidelines on myocardial revascularization European Heart Journal (2018) 00, 1?96 doi:10.1093/eurheartj/ehy394
  14. Pandey A, McGuire DK, de Lemos JA, Das SR, Berry JD, Brilakis ES, Banerjee S, Marso SP, Barsness GW, Simon DN, Roe M, Goyal A, Kosiborod M, Amsterdam EA, Kumbhani DJ. Revascularization trends in patients withdiabetesmellitus and multivesselcoronaryarterydiseasepresentingwithnon-STelevationmyocardialinfarction: insights from the National Cardiovascular Data Registry Acute CoronaryTreatment and Intervention Outcomes Network Registry-Getwith the Guidelines (NCDR ACTION Registry-GWTG). CircCardiovascQualOutcomes 2016; 9: 197-205.

[Sanoussi Hamza , Hasni Mohammed Ali , Kourireche Najla and Lakhal Zouhair. (2018); IMPACT OF TYPE 2 DIABETES IN NON ST-ELEVATION MYOCARDIAL INFARCTION (NSTEMI). Int. J. of Adv. Res. 6 (Dec). 1029-1033] (ISSN 2320-5407). www.journalijar.com

SANOUSSI HAMZA
Cardiology department, Military hospital, Rabat, Morocco

DOI:

Article DOI: 10.21474/IJAR01/8231      
DOI URL: https://dx.doi.org/10.21474/IJAR01/8231

Download Full Paper

Download PDF No. of Downloads: 27 | No. of Views: 113